All Products
Jardiance
Type 2 diabetes mellitus
Glycaemic control1:
JARDIANCE is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.
Add-on combination therapy:
In combination with glucose-lowering medicines, including metformin, a thiazolidinedione, a sulphonylurea, a DPP-4 inhibitor, or insulin, when these together with diet and exercise, do not provide adequate glycaemic control.
Prevention of cardiovascular events1:
JARDIANCE is indicated in patients with type 2 diabetes mellitus and high cardiovascular risk* to reduce the risk of:
• cardiovascular death due to myocardial infarction
• cardiovascular death or hospitalisation for heart failure.
*e.g. previous myocardial infarction, multi vessel coronary artery disease,
previous coronary revitalisation, single vessel coronary disease, at least 50 %
narrowing of coronary artery lumen.
Heart failure (HF)1:
JARDIANCE is indicated in adult patients with heart failure (NYHA class II-IV) independent of left ventricular ejection fraction, with or without type 2 diabetes mellitus:
• to reduce the risk of cardiovascular death and hospitalisation for heart failure
• to slow kidney function decline.
1. Jardiance package insert (10 July 2023) – PC-ZA-102326
Synjardy
Glycaemic control2:
SYNJARDY is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus who have been stabilised on co- administration of the two component medicines.
Prevention of cardiovascular events2:
SYNJARDY is indicated in patients with type 2 diabetes mellitus and high cardiovascular risk to reduce the risk of cardiovascular death or hospitalisation for heart failure.
2. Synjardy package insert - PC-ZA-102661
OFEV
OFEV is indicated in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF). OFEV is also indicated in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (see section 5.1). OFEV is indicated in adults for the treatment of systemic sclerosis associated interstitial lung disease (SSc-ILD).3
3. OFEV package insert (10 December 2021) – PC-ZA-102627
Twynsta
TWYNSTA tablets contain two active substances called telmisartan and amlodipine.
TWYNSTA is used to treat high blood pressure (also known as essential hypertension) in patients using the same components as individual components, or when treatment with amlodipine alone did not lower your blood pressure enough.4
4. Twynsta package insert (28 June 2021) - PC-ZA-102662
Actilyse
Actilyse is indicated for Fibrinolytic therapy in acute myocardial infarction for patients in whom treatment can be started within 6 hours of symptom onset.
Thrombolytic (fibrinolytic) treatment in patients with acute massive pulmonary embolism with haemodynamic instability. Thrombolytic (fibrinolytic) treatment of acute ischaemic stroke.5
Actilyse package insert (25 May 2023) – PC-ZA-102638